HEDERAGENIN

Possibly Marketed Outside US

First approved in 2018

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H48O4
Molecular Weight	472.6997
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]3(C)C2=CC[C@]4([H])[C@@]5(C)CC[C@H](O)[C@@](C)(CO)[C@]5([H])CC[C@@]34C)C(O)=O

InChI

InChIKey=PGOYMURMZNDHNS-MYPRUECHSA-N

InChI=1S/C30H48O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C30H48O4
Molecular Weight	472.6997
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26557859 | https://www.ncbi.nlm.nih.gov/pubmed/26481049

Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κB. Hederagenin exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepression, anti-inflammation.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Apoptosis 155 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25342273	Activator 1430		1.39 µM [IC50]
Pancreatic elastase 3 Target ID: CHEMBL2096984 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8554461	Inhibitor 8297		40.6 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Atherosclerosis 74 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26557859	Primary	Preclinical	Unknown Approved Use Unknown
Colon cancer 62 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25342273 https://www.ncbi.nlm.nih.gov/pubmed/23992864	Primary	Basic research	Unknown Approved Use Unknown
Venous insufficiency 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8554461	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats.	2015	26557859
Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice.	2015 Dec	26481049

Patents

Sample Use Guides

In Vivo Use Guide

Hederagenin, dissolved in 40% polyethylene glycol, was administered orally to mice at doses of 5 or 30 mg/kg/day for four consecutive days.

Route of Administration: Oral

In Vitro Use Guide

Treatment with hederagenin (10, 30 and 100uM) resulted in inhibited levels of protein expression of lipopolysaccharide-stimulated iNOS, COX-2, and NF-κB as well as production of NO, PGE2, TNF-α, IL-1β, and IL-6 induced by lipopolysaccharide in RAW 264.7 cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:43:14 GMT 2023` Edited by `admin` on `Fri Dec 15 19:43:14 GMT 2023`
Record UNII	RQF57J8212
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HEDERAGENIN

Common Name

English

ASTRANTIAGENIN E

Common Name

English

OLEAN-12-EN-28-OIC ACID, 3,23-DIHYDROXY-, (3.BETA.,4.ALPHA.)-

Common Name

English

OLEAN-12-EN-28-OIC ACID, 3.BETA.,23-DIHYDROXY-

Common Name

English

CAULOSAPOGENIN

Common Name

English

HEDERAGENIC ACID

Common Name

English

HEDERAGENIN [MI]

Common Name

English

HEDERAGENIN, (+)-

Common Name

English

HEDERAGENOL

Common Name

English

HEDERAGENINE

Common Name

English

NSC-24954

Code

English

Code System Code Type Description

FDA UNII

RQF57J8212